Table 4.
Neuroactive steroids in the sciatic nerve of male and female control and diabetics
| Male | Female | |||
|---|---|---|---|---|
| Ctrl | STZ | Ctrl | STZ | |
| Progesterone | 3.17 ± 0.3 | 3.21 ± 0.5 | 5.68 ± 0.7 | 4.00 ± 0.3 |
| Dihydroprogesterone | 1.15 ± 0.5 | 1.92 ± 0.7 | 17.60 ± 3.6 | 16.30 ± 3.2 |
| Allopregnanolone | 3.28 ± 0.2 | 7.63 ± 1.7*** | 10.50 ± 0.9 | 10.70 ± 1.4 |
| Isopregnanolone | 0.37 ± 0.1 | 0.27 ± 0.1 | 16.40 ± 2.2 | 16.80 ± 4.1 |
| Testosterone | 2.59 ± 0.6 | 0.55 ± 0.4*** | 0.42 ± 0.1 | 0.35 ± 0.1 |
| Dihydrotesterone | 12.10 ± 0.8 | 2.23 ± 0.6*** | UDL | UDL |
| 5α-Androstane-3α 17β-diol | 0.95 ± 0.5 | 0.31 ± 0.2 | 0.66 ± 0.3 | 0.10 ± 0.1 |
| 5α-Androstane-3β 17β-diol | 5.40 ± 1.3 | 4.50 ± 0.6 | 4.21 ± 1.0 | 5.92 ± 0.6 |
| 17α -Estradiol | 0.56 ± 0.1 | 0.63 ± 0.1 | 0.67 ± 0.1 | 0.74 ± 0.1 |
| 17β -Estradiol | 0.43 ± 0.1 | 0.44 ± 0.1 | 0.78 ± 0.3 | 0.60 ± 0.7 |
Neuroactive steroid levels were evaluated by liquid chromatography tandem mass spectrometry. Data are expressed as pg/mg of tissue ± SEM. The number of animals utilized was 6. Analysis by Student’s t test ***p < 0.001 vs Ctrl
Ctrl control, STZ diabetics, UDL under detection limit